CENNA BIOSCIENCES INC

Biotech · Private

Modified P8 (mP8), an 8-amino acid peptide therapeutic that inhibits amyloid-beta production for Alzheimer's disease treatment

Grants
$14M
16 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Intranasal Delivery of Peptide Drugs to the Brain$750,000
Federal grantDepartment of Health and Human Services · Phase II · Intranasal Delivery of Peptide Drugs to the Brain$746,899
Federal grantDepartment of Health and Human Services · Phase I · Small molecule therapeutics for Alzheimer's Disease$225,000
Federal grantDepartment of Health and Human Services · Phase I · Small molecule therapeutics for Alzheimer's Disease$225,000
Federal grantDepartment of Health and Human Services · Phase II · Intranasal Delivery of Peptide Drugs to the Brain$99,960
Federal grantDepartment of Health and Human Services · Phase II · Progressing the Pre-clinical development of P8 for Alzheimer's Disease$750,000
Federal grantDepartment of Health and Human Services · Phase II · Progressing the Pre-clinical development of P8 for Alzheimer's Disease$747,850
Federal grantDepartment of Health and Human Services · Phase II · Small molecule therapeutics for Alzheimer's Disease$999,998
Federal grantDepartment of Health and Human Services · Phase II · Small molecule therapeutics for Alzheimer's Disease$2,374,496
Federal grantDepartment of Health and Human Services · Phase II · Small molecule therapeutics for Alzheimer's Disease$999,998
Federal grantDepartment of Health and Human Services · Phase II · Small molecule therapeutics for Alzheimer's Disease$374,500
Federal grantDepartment of Health and Human Services · Phase II · IND-Enabling Pre-clinical Development of Modified P8 for the Treatment of Alzheimer's Disease$1,750,000
Federal grantDepartment of Health and Human Services · Phase II · IND-Enabling Pre-clinical Development of Modified P8 for the Treatment of Alzheimer's Disease$1,610,358
Federal grantDepartment of Health and Human Services · Phase II · IND-Enabling Pre-clinical Development of Modified P8 for the Treatment of Alzheimer's Disease$101,144
Federal grantDepartment of Health and Human Services · Phase II · Early Clinical Development Of Modified P8 For The Treatment Of Alzheimer's Disease$1,041,646
Federal grantDepartment of Health and Human Services · Phase II · Early Clinical Development Of Modified P8 For The Treatment Of Alzheimer's Disease$1,633,354
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2181General Counsel AI, Inc.—$63M
2182GIWOTECH INC.——
2183City Therapeutics——
2184CENNA BIOSCIENCES INC——
2185OCULOGENEX——
2186BIOSUPERIOR TECHNOLOGY INC——
2187NexImmune, Inc.—$35M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Novel Peptides And Uses Thereofapplication
  • Novel Peptides And Uses Thereofapplication
  • Novel Peptides And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.